Market Highlights:

According to Market Research Future (MRFR)s new study, the global irritable bowel syndrome treatment market Share is projected to thrive at a CAGR of 7.58% during the forecast period.

The irritable bowel syndrome treatment market is garnering substantial traction. Market growth attributes to the highly prevailing irritable bowel complications. Besides, the rising demand for effective treatment methods drives the growth of the market. Also, rising breakthrough discoveries of drugs and therapeutics accelerate market growth. Moreover, the strong drug pipeline for IBS escalates the market growt

Also, improving healthcare infrastructures including hospitals & clinics, research laboratories, foster the growth of the market. Additionally, factors such as several risk factors leading to IBS, like changing dietary patterns, sedentary lifestyle, and extensive use of antibiotics, boost market growth.

Conversely, significant unmet clinical needs and lack of awareness for IBS treatments are major factors predicted to impede the market growth. However, rising clinical study designs that have received a non-significant risk determination from the FDA would contribute to the market growth throughout the analyzed period.

Global Market for Irritable Bowel Syndrome Treatment Segmental analysis:
This MRFR report offers a detailed segmental analysis of the global irritable bowel syndrome treatment market based on type, drug type, and end-user. By type, the market has been segmented into IBS-C, IBS-D, and IBS-M. Among these, IBS-D segment is currently dominating the global market and is projected to retain its dominance in the upcoming years. Its valuation is poised to reach USD 1790.6 Mn striking a CAGR of 8.31% over the assessment period.

By drug type, the irritable bowel syndrome treatment market has been segmented into lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron, and others. The linaclotide segment is expected to grow significantly in the foreseeable future. It is anticipated to mark a relatively higher CAGR of 7.95% through the projection period. The growth trajectory of the segment is forecasted to be dictated by the increasing collaborations among the key players.

By end-user, the market is segmented into hospitals, clinics, research laboratories, and others. Among these, the hospital segment accounts for the maximum share of the irritable bowel syndrome treatment market and is presumed to thrive at a comparatively higher CAGR across the review period. The factors that are likely to drive the expansion of the segment in the forthcoming years include the rising number of hospitals, increasing demand for affordable treatments, and growing patient population.                                                                                                     

Regional Outlook:
North America leads the global irritable bowel syndrome treatment market. The region accounted for over 45% of the overall market share in 2017. The largest market share attributes to the presence of several notable industry players, complex regional pain syndrome research study and well-established healthcare sector. Also, the growing prevalence of irritable bowel syndrome and diseases related to IBS drive the market demand.

Moreover, the well-spread awareness among demographics about IBS treatments, alongside the rising uptake of IBS diagnostics and treatment devices, fosters market revenues. Furthermore, favorable healthcare reimbursement policies positively impact the growth of the regional market. The US IBS treatment market holds the largest share in the regional market. 

Europe holds the second-largest position in the global irritable bowel syndrome treatment market. The market is driven by the increasing per capita healthcare expenses and penetration of healthcare sectors in the region. The presence of large patient pool and major pharma companies in the region boost market growth. Moreover, the availability of effective medications and R & D funding support from public & private sectors propels the regional market growth.

Additionally, rising drugs & therapeutics discoveries and the resurging economy in the region foster market growth, allowing access to quality medication and hence, excellent care. IBS treatment markets in the UK, Germany, and France, along with the breakthrough drug discovery and burgeoning pharmaceutical industry, significantly contribute to the regional market growth. The European IBS treatment market is projected to create a larger revenue pocket over the assessment period.

The Asia Pacific irritable bowel syndrome treatment market is growing rapidly. Factors such as the increasing healthcare expenditures, burgeoning pharma sector, and favorable government policies boost the regional market growth. Furthermore, the large unmet clinical needs and raw material advantage foster the market growth in the region. Rapidly developing economies like as India and China contribute to the regional market growth majorly. The APAC IBS treatment market is expected to witness a spurting growth over the projected period.

Global Market for Irritable Bowel Syndrome Treatment Competitive Dashboard:
Some of the key players profiled in the report are Abbott, Allergan Inc., Ardelyx Inc., Astellas Pharma, Inc., Ironwood Pharmaceuticals, Lexicon Pharmaceuticals, Inc., Mallinckrodt, Nestle Health Science, Synergy Pharmaceuticals Inc., and Valeant Pharmaceuticals International, Inc.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com